Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 9

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 9
---
 if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes in favor of Proposal Nos.1,2, 3 or 4 (the “Adjournment Proposal” or “Proposal No. 7”). How does the Board recommend that I vote? The Company’s Board recommends that you vote your shares: • “FOR” Proposal No. 1:The approval of an amendment to our Certificate of Incorporation to combine outstanding shares of our Common Stock into a lesser number of outstanding shares, by a ratio of not less than one -for- and not more than one -for- , with the exact ratio to be set within this range by our Board in its sole discretion. • “FOR” Proposal No. 2:The approval, subject to certain conditions, of the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635, upon the exercise of February 2025 Common Warrants issued in the February 2025 Registered Direct Offering at less than the “minimum price” under Nasdaq Listing Rule 5635(d), including the issuance of equity compensation to one of the Company’s directors upon the exercise of the February 2025 Common Warrants at less than market value pursuant to Nasdaq Listing Rule 5635(c). • “FOR” Proposal No. 3:The approval, subject to certain conditions, of the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635, upon conversion of the Series D Preferred Stock issued in the April 2025 Private Placement. • “FOR” Proposal No. 4 :The approval of the 2024 Plan, as amended to increase the number of shares of Common Stock available for issuance under the 2024 Plan and the number of shares that may be issued pursuant to incentive stock options by an additional shares. • “FOR” Proposal No. 5 :The approval of the election of two Class I directors to the Board, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. • “FOR” Proposal No. 6 :The ratification of the appointment of Wolf, as the Company’s independent registered public accounting firm for the 2025 fiscal year. • “FOR” Proposal No. 7 :The approval of an adjournment of the Annual Meeting, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes